Editas Medicine, Inc. (EDIT) Stock Price & Analysis

Editas Medicine, Inc. (EDIT) rose 4.87% to USD 3.23 as of September 8, 2026 at 04:21 UTC, according to Nexqual real-time market data.

EDIT last closed at USD 3.23; the session ranged USD 3.04–3.23 on volume of 1,390,713 shares. Market capitalization is —, with a 52-week range of USD 1.66–4.54 (NMS). Source: Nexqual, September 8, 2026 at 04:21 UTC.

Key Statistics (as of September 8, 2026 at 04:21 UTC)

Technical Analysis (EDIT)

Nexqual's technical model rates EDIT "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 04:21 UTC.

From Editas Medicine, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)

Key Strengths & Strategy (as disclosed to the SEC)

• Our Gene Editing Platform We have developed a proprietary gene editing platform that includes different natural and engineered variants of Cas9 and Cas12a.
• In December 2023, we and Vertex Pharmaceuticals Incorporated ("Vertex") entered into a license agreement (the "Vertex License Agreement"), under which Vertex obtained a non-exclusive license for our Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of SCD and TDT, including Vertex's CASGEVY TM (exagamglogene autotemcel).
• We have developed a proprietary gene editing platform based on CRISPR technology and we continue to expand its capabilities.
• We believe we are the only human gene editing company with a platform that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms of both of these CRISPR systems, and foundational intellectual property for both of these CRISPR systems.

Partnerships

• Examples of these licensing efforts include our non-exclusive license to Vertex for our Cas9 gene editing 11 Table of Co ntents technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of SCD and TDT, including Vertex's CASGEVY TM (exagamglogene autotemcel); our non-exclusive license to Immatics of our AsCas12a technology to advance gamma-delta T cell therapies for the treatment of cancer; and our collaboration with BMS.
• In connection with the amendment and restatement in November 2019, we entered into a license agreement with BMS (such agreement, the "BMS License Agreement," and together with the BMS Collaboration Agreement, the "BMS Agreements").

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:21 UTC. This page is informational and not investment advice.